Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, achievements, and what lies ahead for Cartherics in its quest to bring innovative solutions to patients worldwide. Watch the interview here: